Tsingke Biotech (Biotechnology, Health Care) — Funding, Investors & Signals 2026

Tsingke Biotech

Leading DNA/RNA synthesis innovator, delivering advanced synthetic genomics products for groundbreaking genetic research

Founded 2004 China

Beijing, China 13 employees Series B Total: $600.00M Biotechnology, Health Care

Tsingke Biotech is a leading innovator in DNA/RNA synthesis, providing advanced synthetic genomics products for pioneering genetic research. Founded in 2017 and headquartered in China, Tsingke Biotech is positioned as an independent gene synthesis platform company with a comprehensive industry chain. The company's diverse business scope encompasses synthetic genomics products and services, life science research equipment and raw materials, and Bio-manufacturing CXO. The company's distinctive proposition lies in its development of the "Gene Factory", establishing a synthesis platform comprising a production facility for raw materials and equipment in gene synthesis elements, a gene intelligent molecule splitting and assembly technology platform, and an intelligent AI algorithm platform propeller system (TSINGKE HELIXTECH). This infrastructure enables Tsingke to offer customers a range of services including gene synthesis, antibody proteins, gene regulation, testing, reagents, instruments, and technical services. With a mission focused on "Biotech for a better world" and guided by the values of "Quality, Innovation, Striving, and Win-win", Tsingke Biotech has garnered significant attention in the biotechnology and healthcare industries. The company recently secured a CNY400.00M Series B investment on 05 December 2022, with participation from notable investors including Qingsong Fund, Fortune Venture Capital, Capitallink, Jolmo Capital, Zhongyuan Asset Management, and Henan CICC Huirong Fund Management. Tsingke Biotech's commitment to pioneering innovations in biomanufacturing positions it as a key player in shaping the future of the industry. Its focus on industry needs and dedication to continuous improvement make it an intriguing prospect for investors and a driving force in advancing genetic research and biotechnology. Follow their LinkedIn page for the latest updates and insights on this captivating journey of innovation and discovery.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	••••••	7	•••• ••••	05 Dec 2022
Series A	••••••	3		01 Jan 2022

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

••••••

•••• ••••

05 Dec 2022

Series A

••••••

01 Jan 2022

FAQ About Tsingke Biotech

Leading DNA/RNA synthesis innovator, delivering advanced synthetic genomics products for groundbreaking genetic research

Tsingke Biotech was founded in 2004.

Tsingke Biotech is headquartered in Beijing, China.

Tsingke Biotech operates in the following industries: Biotechnology, Health Care.

Tsingke Biotech has approximately 13 employees.

Tsingke Biotech has completed 2 funding rounds, raising a total of $600.00M. The latest funding stage is Series B.

Top alternatives and competitors to Tsingke Biotech include Codex DNA, DNA2.0 (now ATUM), Bohai New Enzyme, SynHelix, Novici Biotech. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Tsingke Biotech and Codex DNA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Tsingke Biotech

General Information

Track Tsingke Biotech

Discover More

About Tsingke Biotech

Funding Rounds & Investors (2)

Tsingke Biotech Alternatives & Competitors

FAQ About Tsingke Biotech

Don't just browse. Track.